vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $55.8333.

VTVT has been the topic of several recent analyst reports. BTIG Research increased their target price on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Zacks Research lowered vTv Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price on the stock. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, HC Wainwright reduced their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th.

vTv Therapeutics Trading Up 4.0%

NASDAQ:VTVT opened at $31.31 on Tuesday. vTv Therapeutics has a 12 month low of $14.55 and a 12 month high of $44.00. The company has a 50-day moving average price of $33.25 and a 200-day moving average price of $34.73. The stock has a market cap of $123.33 million, a price-to-earnings ratio of -29.54 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Equities analysts forecast that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics in the 4th quarter worth approximately $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter valued at $731,000. Finally, Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.